Rhode Island House Bill H7720

Rhode Island 2026 Regular Session

• Introduced: 2/12/26
• Refer: 2/12/26

Caption

Requires a healthcare entity to submit written notice to the attorney general and the department of health of any material change transaction at least 180 days prior to that transaction.

Impact

The legislation is designed to enhance oversight of the healthcare system in Rhode Island, particularly in light of recent financial difficulties faced by local medical facilities. By requiring thorough reviews of material change transactions, the bill seeks to ensure that such actions do not lead to increased costs or reduced access to essential healthcare services. The attorney general and department of health are tasked with conducting a comprehensive cost and market impact review to assess the implications of such transactions on overall healthcare delivery, affordability, and service availability, particularly within underserved communities.

Summary

House Bill 7720, known as the Rhode Island Healthcare Transaction Oversight Act, introduces stringent requirements for healthcare entities regarding major financial transactions. Specifically, the bill mandates that any healthcare provider intending to undergo significant changes—such as mergers or acquisitions—must provide written notice to the Rhode Island attorney general and the department of health at least 180 days prior to the transaction. This proactive measure aims to protect the health and safety of Rhode Islanders by intervening before potentially harmful changes can destabilize healthcare services and access in the community.

Contention

As healthcare consolidations have been linked with rising costs and reduced access, the introduction of HB 7720 reflects a growing concern over corporate control in health services. Proponents of the bill argue that it is essential for safeguarding public health against corporate practices that prioritize profit over patient care. Conversely, critics may view these requirements as potential hurdles that could hinder necessary mergers or expansions, arguing that they might introduce delays or complexities that dissuade beneficial investments in the healthcare system.